| 1 |
NCT01567202 |
Recruiting |
Study of DC Vaccination Against Glioblastoma |
- Glioma
- Glioblastoma Multiforme
- Neoplasms
|
- Procedure: Surgery
- Drug: Chemotherapy
- Radiation: Radiotherapy
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Huashan Hospital
- Fudan University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Objective response rate (ORR) of the treatment using DC Vaccination for Glioblastoma with molecular markers for immunotherapy.
- Progression free survival
- Overall survival
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01567202 |
DC81001115 |
|
March 2012 |
December 1, 2019 |
February 1, 2020 |
March 30, 2012 |
February 1, 2019 |
|
- Huashan hospital, Fudan university
Shanghai, Shanghai, China
|
|
| 2 |
NCT02465268 |
Recruiting |
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme |
- Glioblastoma Multiforme
- Glioblastoma
- Malignant Glioma
- (and 2 more...)
|
- Biological: pp65-shLAMP DC with GM-CSF
- Biological: unpulsed PBMC and saline
- Drug: Td
- (and 2 more...)
|
Interventional
|
Phase 2 |
- University of Florida
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Change in median overall survival
- Changes in immune response
- Change in progression-free survival
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT02465268 |
IRB201400697-N
R01CA175517
OCR14127 |
ATTAC-II |
August 2016 |
June 2023 |
June 2024 |
June 8, 2015 |
January 24, 2019 |
|
- University of Florida
Gainesville, Florida, United States - Orlando Health
Orlando, Florida, United States - Duke University Medical Center
Durham, North Carolina, United States
|
|
| 3 |
NCT03334305 |
Recruiting |
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas |
|
- Biological: TTRNA-DC vaccines with GM-CSF
- Drug: Dose-intensified TMZ
- Biological: Autologous Hematopoietic Stem cells (HSCs)
- (and 2 more...)
|
Interventional
|
Phase 1 |
- University of Florida
- National Pediatric Cancer Foundation
- National Cancer Institute (NCI)
- (and 2 more...)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate safety of TTRNA-DCs and TTRNA-xALT
- Determine feasibility of completing treatment
- Anti-tumor immune responses
- (and 2 more...)
|
8 |
All |
3 Years to 21 Years (Child, Adult) |
NCT03334305 |
IRB201701867-N
R01CA195563
OCR15852 |
ACTION |
May 16, 2018 |
May 2022 |
May 2026 |
November 7, 2017 |
December 28, 2018 |
|
- UF Health Shands Children's Hospital
Gainesville, Florida, United States
|
|
| 4 |
NCT03395587 |
Recruiting |
Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma |
|
- Biological: Autologous, tumor lysate-loaded, mature dendritic cells (DC)
- Drug: standard therapy
|
Interventional
|
Phase 2 |
- Heinrich-Heine University, Duesseldorf
- German Federal Ministry of Education and Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression free survival (PFS)
- OS rates
- (and 8 more...)
|
136 |
All |
18 Years and older (Adult, Older Adult) |
NCT03395587 |
GlioVax |
GlioVax |
March 6, 2018 |
September 6, 2022 |
June 6, 2023 |
January 10, 2018 |
January 9, 2019 |
|
- Klinik für Neurologie, Knappschaftskrankenhaus Bochum
Bochum, Northrhine Westphalia, Germany - Klinik für Neurochirurgie, Sana Kliniken Duisburg
Duisburg, Northrhine Westphalia, Germany - Neurochirurgische Klinik, Universitätsklinikum Düsseldorf
Düsseldorf, Northrhine Westphalia, Germany - (and 2 more...)
|
|
| 5 |
NCT02649582 |
Recruiting |
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients |
- Glioblastoma Multiforme of Brain
|
- Biological: Dendritic cell vaccine plus temozolomide chemotherapy
|
Interventional
|
Phase 1
Phase 2 |
- University Hospital, Antwerp
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Number of glioblastoma patients post surgical resection with feasible and safe DC vaccine production
- Feasibility of DC vaccine administration to glioblastoma patients combined with chemotherapy
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02649582 |
CCRG14-001 |
ADDIT-GLIO |
December 2015 |
December 2020 |
December 2022 |
January 7, 2016 |
May 24, 2018 |
|
- Antwerp University Hospital
Edegem, Antwerp, Belgium
|
|
| 6 |
NCT03360708 |
Not yet recruiting |
Vaccine Therapy and Cytokine-Induced Killer Cells in Treating Patients With Recurrent Glioblastoma |
- Giant Cell Glioblastoma
- Recurrent Glioblastoma
- Recurrent Gliosarcoma
|
- Biological: Cytokine-Induced Killer Cells
- Other: Laboratory Biomarker Analysis
- Biological: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
|
Interventional
|
Early Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of significant toxicity, defined as a dose limiting toxicity (DLT) that is possibly, probably, or definitely related to treatment as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Clinical benefit rate
- Duration of response
- (and 5 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03360708 |
MC1772
NCI-2017-02159
P30CA015083 |
|
March 30, 2019 |
December 1, 2022 |
December 1, 2022 |
December 4, 2017 |
February 19, 2019 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 7 |
NCT03014804 |
Not yet recruiting |
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma |
- Giant Cell Glioblastoma
- Gliosarcoma
- Oligodendroglioma
- (and 2 more...)
|
- Biological: autologous dendritic cells pulsed with tumor lysate antigen Vaccine
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Northwest Biotherapeutics
- Bristol-Myers Squibb
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events assessed by National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03
- Overall Survival (OS)
- Overall Survival rate
- (and 8 more...)
|
30 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03014804 |
16-001706
NCI-2016-01587
P30CA016042 |
|
January 1, 2019 |
January 1, 2020 |
January 1, 2022 |
January 9, 2017 |
October 24, 2018 |
|
- UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
|
|
| 8 |
NCT03548571 |
Recruiting |
Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy |
|
- Biological: Dendritic cell immunization
- Drug: Adjuvant temozolomide
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Overall survival
- Patient reported quality of life, overall
- (and 4 more...)
|
60 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03548571 |
DEN-STEM |
DEN-STEM |
April 26, 2018 |
May 1, 2020 |
May 1, 2023 |
June 7, 2018 |
June 7, 2018 |
|
- Oslo University Hospital
Oslo, Norway
|
|
| 9 |
NCT03688178 |
Not yet recruiting |
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab |
|
- Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
- Drug: Temozolomide
- Biological: Varlilumab
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Gary Archer Ph.D.
- Celldex Therapeutics
- Duke University
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Median Overall Survival (OS) of Subjects Receiving Td pre-conditioning
- Safety of administering Varlilumab to GBM patients receiving temozolomide and dendritic cell vaccines ± Td pre-conditioning as measured by the percentage of patients with unacceptable toxicity regardless of attribution
- Median percent change between baseline, assessed on day 14, and nadir levels of Treg before the time that the second cycle of adjuvant TMZ would be administered. Treg determined by flow cytometry (CD3+ CD4+ CD25+ Foxp3+).
- (and 4 more...)
|
112 |
All |
18 Years and older (Adult, Older Adult) |
NCT03688178 |
Pro00082570 |
DERIVe |
March 2019 |
March 1, 2025 |
March 1, 2025 |
September 28, 2018 |
January 25, 2019 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
|
| 10 |
NCT02709616 |
Recruiting |
Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC) |
|
- Biological: Personalized cellular vaccine
|
Interventional
|
Phase 1
Phase 2 |
- Guangdong 999 Brain Hospital
- Jinan University Guangzhou
- Beijing Tricision Biotherapeutics Inc
- Guangzhou Trinomab Biotech Co., Ltd.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of treatment-emergent adverse events and severe adverse events [safety and Tolerability]
- Antitumor antigen specific T cell response
- Progression-free survival
- Overall survival
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02709616 |
Ag-mRNA-DC-999brain |
PERCELLVAC |
March 2016 |
March 2018 |
June 2019 |
March 16, 2016 |
June 20, 2016 |
|
- Guangdong 999 Brain Hospital
Guangzhou, Guangdong, China
|
|
| 11 |
NCT03400917 |
Recruiting |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
- Newly Diagnosed Glioblastoma
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary Efficacy Endpoint: Overall Survival
|
55 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03400917 |
CL-GBM-P01 |
|
June 20, 2018 |
October 2020 |
June 2023 |
January 17, 2018 |
January 7, 2019 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States - UC Irvine Medical Center
Orange, California, United States - (and 4 more...)
|
|
| 12 |
NCT01326104 |
Recruiting |
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor |
- Medulloblastoma
- Neuroectodermal Tumor
|
- Biological: TTRNA-xALT
- Biological: TTRNA-DCs
|
Interventional
|
Phase 1
Phase 2 |
- University of Florida
- United States Department of Defense
|
Other / U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate safety of TTRNA-DCs and TTRNA-xALT
- Determine progression-free survival
- Determine Objective Radiographic Response Rate
- (and 5 more...)
|
35 |
All |
up to 30 Years (Child, Adult) |
NCT01326104 |
IRB201500502
W81XWH-10-1-0089
CDMRP-PRO93877
OCR13166 |
Re-MATCH |
April 2010 |
March 2019 |
March 2020 |
March 30, 2011 |
December 28, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Stanford University
Palo Alto, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - (and 2 more...)
|
|
| 13 |
NCT02146066 |
Available |
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
- GBM
- Glioblastoma Multiforme
|
|
Expanded Access
|
|
- Northwest Biotherapeutics
|
Industry |
|
|
|
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02146066 |
0202EA |
DCVax-L EAP |
|
|
|
May 23, 2014 |
February 26, 2016 |
|
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - UCLA Medical Center
Los Angeles, California, United States - Hoag Memorial Hospital
Newport Beach, California, United States - (and 24 more...)
|
|
| 14 |
NCT03392545 |
Recruiting |
Combination of Immunization and Radiotherapy for Recurrent GBM (InSituVac1) |
|
- Combination Product: Combined immune adjuvants and radiation
|
Interventional
|
Phase 1 |
- Beijing Tiantan Hospital
- Duke University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-related Adverse Events
- Progression-free Survival
- Overall Survival
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03392545 |
B0011 |
InSituVac1 |
April 1, 2018 |
April 1, 2020 |
June 1, 2020 |
January 8, 2018 |
October 2, 2018 |
|
- Beijing Tiantan Hospital
Beijing, Beijing, China
|
|
Create an RSS feed from your search for:
Download the search results for: